

Atty. Docket No. P29215

Application No. 10/565,997

ITW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ryozo NAGAI et al.

Confirmation No.: 9551

Appln. No. : 10/565,997

Group Art Unit: 1653

Filed : January 27, 2006

Examiner: Not Yet Assigned

For : RNA CAPABLE OF SUPPRESSING EXPRESSION OF KLF5 GENE

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop \_\_\_\_\_  
Randolph Building  
401 Dulany Street  
Alexandria VA 22314

Sir:

Further to the Information Disclosure Statement filed August 14, 2006, and in accordance with the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants hereby call to the Office's attention the following information, which includes documents cited in a Supplementary European Search Report dated September 5, 2007, issued in connection with corresponding European Application No. EP 04 77 1250:

NANDAN et al., "Kruppel-Like Factor 5 (KLF5) Mediates HA-RAS-Induced Cell Transformation," Digestive Disease Week Abstracts and Itinerary Planner, Vol. 2003, Abstract No. 446 (2003);

MIYAGISHI et al., "U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells," Nature Biotechnology, Vol. 20, No. 5, pages 497-500 (2002); and

NANDAN et al., "Kruppel-like factor 5 mediates the transforming activity of oncogenic H-Ras," Oncogene, Vol. 23, No. 19, pages 3404-3413 (2004).


Copies of the above-listed documents and the Supplementary Search Report for European Application No. 04 77 1250 are enclosed together with a completed copy of the PTO-1449 Form listing these documents. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next official communication.

Applicants note that while this Supplemental Information Disclosure Statement is being filed more than three months from the filing date, Applicants have not received an action on the merits from the U.S. Patent and Trademark Office. Accordingly, consideration of the enclosed documents are required under 37 C.F.R. 1.97(b)(3).

However, if an action on the merits has been mailed prior to the filing date of this Supplemental Information Disclosure Statement, Applicants hereby authorize the charging of any required fees necessary for consideration of the documents cited herein to Deposit Account No. 19-0089.

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,  
Ryozo NAGAI et al.

  
Bruce H. Bernstein  
Reg. No. 29,027 42,920

December 4, 2007  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191